Responses
Clinical/translational cancer immunotherapy
Original research
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses
Compose a Response to This Article
Other responses
No responses have been published for this article.